Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients
Objective: To investigate the long-term characteristic changes of virus, immune status, and liver fibrosis markers in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients after receiving direct-antiviral agents (DAAs). Methods: HIV/HCV co-infected patients who visited the Guangzhou Eighth People's Hospital, Guangzhou Medical University from May 2014 to December 2019 were selected as the research subjects. The changes of virological response rate, peripheral blood CD4(+)T lymphocyte level and serological markers of liver fibrosis (APRI score and FIB-4 index) were observed during 144 weeks of follow-up course after the end of DAAs treatment. Kruskal-Wallis test was used for statistical approach. Results: A total of 103 cases were included in the study. There were 87 males (87.5%), with a median age of 44 years. Sustained virological response rate at 12 weeks (SVR12) after DAAs treatment was 97.6%, and the SVR during the entire follow-up period was at least 95.9%. Compared with baseline, CD4(+)T lymphocyte count were significantly increased equally at 12 weeks (Z = -2.283, P = 0.022), 24 weeks (Z = -3.538, P < 0.001), 48 weeks (Z = -3.297, P = 0.001), 96 weeks (Z = -3.562, P < 0.001), and 144 weeks (Z = -2.842, P = 0.004). APRI score (Z = -6.394, P < 0.001) and FIB-4 index (Z = -2.528, P = 0.011) were significantly lower than baseline at week 4 of DAAs treatment, and thereafter remained at a low level, without further declination. Conclusion: HIV/HCV co-infected patients can maintain high SVR for a long time, acquire good immune reconstitution, and significantly improve liver fibrosis after DAAs treatment.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:29 |
|---|---|
| Enthalten in: |
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology - 29(2021), 8 vom: 20. Aug., Seite 776-780 |
| Sprache: |
Chinesisch |
|---|
| Beteiligte Personen: |
Liao, B L [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antiviral Agents |
|---|
| Anmerkungen: |
Date Completed 15.09.2021 Date Revised 15.09.2021 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.3760/cma.j.cn501113-20201228-00682 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM330596004 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM330596004 | ||
| 003 | DE-627 | ||
| 005 | 20231225211626.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||chi c | ||
| 024 | 7 | |a 10.3760/cma.j.cn501113-20201228-00682 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1101.xml |
| 035 | |a (DE-627)NLM330596004 | ||
| 035 | |a (NLM)34517460 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a chi | ||
| 100 | 1 | |a Liao, B L |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Long-term therapeutic effects and liver fibrosis changes with direct-antiviral therapy in HIV/HCV co-infected patients |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 15.09.2021 | ||
| 500 | |a Date Revised 15.09.2021 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Objective: To investigate the long-term characteristic changes of virus, immune status, and liver fibrosis markers in human immunodeficiency virus (HIV)/hepatitis C virus (HCV) co-infected patients after receiving direct-antiviral agents (DAAs). Methods: HIV/HCV co-infected patients who visited the Guangzhou Eighth People's Hospital, Guangzhou Medical University from May 2014 to December 2019 were selected as the research subjects. The changes of virological response rate, peripheral blood CD4(+)T lymphocyte level and serological markers of liver fibrosis (APRI score and FIB-4 index) were observed during 144 weeks of follow-up course after the end of DAAs treatment. Kruskal-Wallis test was used for statistical approach. Results: A total of 103 cases were included in the study. There were 87 males (87.5%), with a median age of 44 years. Sustained virological response rate at 12 weeks (SVR12) after DAAs treatment was 97.6%, and the SVR during the entire follow-up period was at least 95.9%. Compared with baseline, CD4(+)T lymphocyte count were significantly increased equally at 12 weeks (Z = -2.283, P = 0.022), 24 weeks (Z = -3.538, P < 0.001), 48 weeks (Z = -3.297, P = 0.001), 96 weeks (Z = -3.562, P < 0.001), and 144 weeks (Z = -2.842, P = 0.004). APRI score (Z = -6.394, P < 0.001) and FIB-4 index (Z = -2.528, P = 0.011) were significantly lower than baseline at week 4 of DAAs treatment, and thereafter remained at a low level, without further declination. Conclusion: HIV/HCV co-infected patients can maintain high SVR for a long time, acquire good immune reconstitution, and significantly improve liver fibrosis after DAAs treatment | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Coinfection | |
| 650 | 4 | |a Direct antiviral agent | |
| 650 | 4 | |a Hepatitis C virus | |
| 650 | 4 | |a Human immunodeficiency virus | |
| 650 | 4 | |a Liver fibrosis | |
| 650 | 7 | |a Antiviral Agents |2 NLM | |
| 700 | 1 | |a Li, L H |e verfasserin |4 aut | |
| 700 | 1 | |a Zhong, H L |e verfasserin |4 aut | |
| 700 | 1 | |a Li, H |e verfasserin |4 aut | |
| 700 | 1 | |a Li, Y H |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, S Z |e verfasserin |4 aut | |
| 700 | 1 | |a Wen, C Y |e verfasserin |4 aut | |
| 700 | 1 | |a Hu, F Y |e verfasserin |4 aut | |
| 700 | 1 | |a Lan, Y |e verfasserin |4 aut | |
| 700 | 1 | |a Cai, W P |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology |d 1998 |g 29(2021), 8 vom: 20. Aug., Seite 776-780 |w (DE-627)NLM096493321 |x 1007-3418 |7 nnns |
| 773 | 1 | 8 | |g volume:29 |g year:2021 |g number:8 |g day:20 |g month:08 |g pages:776-780 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3760/cma.j.cn501113-20201228-00682 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 29 |j 2021 |e 8 |b 20 |c 08 |h 776-780 | ||